Key facts
- This page summarizes Khalid Islam's Form 4 filing for Gain Therapeutics, Inc. (GANX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Aug 2024, 17:23.
Khalid Islam - 09 Aug 2024 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)
- Reporting relationship
- Executive Chairman, Director
- Issuer ticker
- GANX
- Reported as of
- 09 Aug 2024
- Net transaction value
- +$49,940
- SEC form
- 4
- Accepted by SEC
- 12 Aug 2024, 17:23:30 UTC
- Prior SEC filing
- 26 Jun 2024
- Next SEC filing
- 19 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Khalid Islam
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Khalid Islam filed Form 4 for Gain Therapeutics, Inc. (GANX) on 12 Aug 2024.
Change
- Previous filing in this sequence was filed on 26 Jun 2024.
- Current net transaction value: +$49,940.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GANX
transaction
Common Stock
Purchase
- Transaction value
- $49,940
- Shares
- +50,000
- Change %
- Price
- $0.9988
- Shares after
- 50,000
- Date
- 09 Aug 2024
- Ownership
- Direct
- Footnotes
- F2
GANX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 880,784
- Date
- 09 Aug 2024
- Ownership
- See footnote
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Reporting Person is the ultimate shareholder of 1 MM & 1 PP AG, which is the direct beneficial owner of the securities.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.9814 to $1.00 per share, inclusive. The reporting person undertakes to provide to Gain Therapeutics, Inc., any security holder of Gain Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.